{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:48:59Z","timestamp":1778888939902,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 157648"],"award-info":[{"award-number":["K24 157648"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL150342"],"award-info":[{"award-number":["R01 HL150342"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL130563"],"award-info":[{"award-number":["R01 HL130563"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 159987"],"award-info":[{"award-number":["R01 159987"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19SRG34950011"],"award-info":[{"award-number":["19SRG34950011"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["AHA 16 CSA 28880004"],"award-info":[{"award-number":["AHA 16 CSA 28880004"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.hfc.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:02:53Z","timestamp":1749582173000},"page":"427-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Anam","family":"Waheed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2025.01.009_bib1","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circulation Heart failure"},{"key":"10.1016\/j.hfc.2025.01.009_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC STATE-OF-THE-ART REview","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib3","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.01.009_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-291X(85)91956-4","article-title":"Localization of the human prealbumin gene to chromosome 18","volume":"129","author":"Wallace","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.hfc.2025.01.009_bib5","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.01.009_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)\u2217 cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.hfc.2025.01.009_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.01.009_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hfc.2025.01.009_bib10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.01.009_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.hfc.2025.01.009_bib12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.01.009_bib13","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"(Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib15","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0002-9149(97)00400-1","article-title":"Right ventricular dilation in primary amyloidosis: an independent predictor of survival","volume":"80","author":"Patel","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib17","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"Journal of Nuclear Cardiology"},{"key":"10.1016\/j.hfc.2025.01.009_bib18","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","article-title":"Light chain amyloidosis: the heart of the problem","volume":"98","author":"Merlini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hfc.2025.01.009_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hfc.2025.01.009_bib21","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circulation Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.hfc.2025.01.009_bib24","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.hfc.2025.01.009_bib25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovascular Imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib26","doi-asserted-by":"crossref","first-page":"e006588","DOI":"10.1161\/CIRCIMAGING.117.006588","article-title":"Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis","volume":"11","author":"Milani","year":"2018","journal-title":"Circulation Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib27","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcmg.2016.04.008","article-title":"Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system","volume":"10","author":"Barros-Gomes","year":"2017","journal-title":"JACC Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"43","author":"Cohen","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.01.009_bib29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.01.009_bib30","doi-asserted-by":"crossref","unstructured":"Aimo A, Merlo M, Porcari A, et al. 2022. P292 REDEFINING THE EPIDEMIOLOGY OF CARDIAC AMYLOIDOSIS. A SYSTEMATIC REVIEW OF SCREENING STUDIES. Eur Heart J, 24(Supplement_C), pp.suac012-281.","DOI":"10.1093\/eurheartj\/suac012.281"},{"key":"10.1016\/j.hfc.2025.01.009_bib31","first-page":"284","article-title":"Binding of serum amyloid P-component (SAP) by amyloid fibrils","volume":"38","author":"Pepys","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.hfc.2025.01.009_bib32","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","article-title":"Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis","volume":"25","author":"Stats","year":"2016","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.hfc.2025.01.009_bib35","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.01.009_bib36","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.01.009_bib37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.CIR.56.2.181","article-title":"Follow-up technetium-99m stannous pyrophosphate myocardial scintigrams after acute myocardial infarction","volume":"56","author":"Olson","year":"1977","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2025.01.009_bib38","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.cardfail.2017.07.128","article-title":"Hydroxychloroquine-Mediated Cardiotoxicity with a False Positive 99M-Technetium Labeled Pyrophosphate Scan for Amyloidosis","volume":"23","author":"Chang","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.hfc.2025.01.009_bib39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"European Heart Journal Cardiovascular Imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2025.01.009_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovascular imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.hfc.2025.01.009_bib43","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovascular Imaging"},{"key":"10.1016\/j.hfc.2025.01.009_bib44","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2025.01.009_bib46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12350-021-02524-x","article-title":"Positron emission tomography for cardiac amyloidosis: timing matters","volume":"29","author":"Singh","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.hfc.2025.01.009_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","article-title":"Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:22:01Z","timestamp":1750148521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713625000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1551713625000091"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2025.01.009","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}